Drugs / RSV F nanoparticle vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01709019 | Oct 2012 → Jul 2013 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV F nanoparticle vaccine | “Four formulations of a novel recombinant RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) administered concurrently with a...” PMID 28413427 ↗ Apr 2017 |
| Modality | Vaccine | “Four formulations of a novel recombinant RSV F nanoparticle vaccine” PMID 28413427 ↗ Apr 2017 |
| Route | Intramuscular | “0.5mL IM injections” NCT01709019 ↗ |